Moving low-risk myelodysplastic syndromes from humans to mice: is it truly that simple?

被引：0
|
作者：
Coriu, Daniel [1 ]
Stancioaica, Maria -Camelia [1 ]
机构：
[1] Carol Davila Univ Med & Pharm, Fundeni Clin Inst, Ctr Hematol & Bone Marrow Transplantat, Bucharest, Romania
来源：
HAEMATOLOGICA | 2024年 / 109卷 / 01期
关键词：
D O I：
10.3324/haematol.2023.283652
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：8 / 10
页数：3
相关论文
共 50 条
  • [31] Luspatercept: a candidate to dethrone erythropoietin in first line in low-risk myelodysplastic syndromes?
    Robert-Van Houtteghem, Tristan
    HEMATOLOGIE, 2023, 29 (05): : 269 - 271
  • [32] Erythroid progenitors from patients with low-risk myelodysplastic syndromes are dependent on the surrounding micro environment for their survival
    Folkerts, Hendrik
    Hazenberg, Carin L. E.
    Houwerzijl, Ewout J.
    van den Heuvel, Fiona A. J.
    Mulder, Andre B.
    van der Want, Johannes J. L.
    Vellenga, Edo
    EXPERIMENTAL HEMATOLOGY, 2015, 43 (03) : 215 - 222
  • [33] Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements
    Angel F. Remacha
    Beatriz Arrizabalaga
    Consuelo Del Cañizo
    Guillermo Sanz
    Ana Villegas
    Annals of Hematology, 2010, 89 : 147 - 154
  • [34] Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements
    Remacha, Angel F.
    Arrizabalaga, Beatriz
    Del Canizo, Consuelo
    Sanz, Guillermo
    Villegas, Ana
    ANNALS OF HEMATOLOGY, 2010, 89 (02) : 147 - 154
  • [35] DNA instability in low-risk myelodysplastic syndromes: refractory anemia with or without ring sideroblasts
    Novotna, Bozena
    Neuwirtova, Radana
    Siskova, Magda
    Bagryantseva, Yana
    HUMAN MOLECULAR GENETICS, 2008, 17 (14) : 2144 - 2149
  • [36] DNA instability in low-risk myelodysplastic syndromes - refractory anemia with or without ring sideroblasts
    Novotna, B.
    Blazkova, V.
    Neuwirtova, R.
    Siskova, M.
    Bagryantseva, Y.
    LEUKEMIA RESEARCH, 2007, 31 : S72 - S72
  • [37] ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS) IN SUPPORTIVE CARE OF LOW-RISK MYELODYSPLASTIC SYNDROMES
    Cerchione, C.
    Martinelli, G.
    Soriente, I.
    D'Arco, A. M.
    Danise, P.
    Cerciello, G.
    Di Battista, V.
    Cangini, D.
    Giannini, M. B.
    Pane, F.
    Alfinito, F.
    HAEMATOLOGICA, 2019, 104 : 147 - 148
  • [38] Pathogenesis of iron overload in myelodysplastic syndromes and the debate on iron chelation in low-risk MDS
    Shenoy, Niraj
    Verma, Amit
    Ginzburg, Yelena
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S85 - S85
  • [39] Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response
    Viniou, N
    Terpos, E
    Galanopoulos, A
    Kritikou-Griva, E
    Akel, S
    Michalis, E
    Apostolidou, E
    Georgiadou, D
    Kouraklis, A
    Parharidou, A
    Kokkini, G
    Symeonidis, A
    Anagnostopoulos, NI
    Christakis, JI
    Tasiopoulou, A
    Loukopoulos, D
    Yataganas, X
    ANNALS OF HEMATOLOGY, 2002, 81 (04) : 182 - 186
  • [40] Limited efficacy of azacitidine, with or without erythropoietin, in low-risk myelodysplastic syndromes resistant to erythropoietin
    Eclache, Virginie
    HEMATOLOGIE, 2016, 22 (05): : 308 - +
12345